What are the currently approved FDA bispecific antibody therapies in multiple myeloma treatment?

As of July 2024, there are three FDA-approved bispecific antibody therapies available to treat multiple myeloma. 

Several bispecific antibodies are in clinical trials and are expected to be approved within the next 2-3 years. This guide will be updated as more bispecific antibodies are approved. 

The three currently approved therapies are: 

• Teclistamab (TECVAYLI), manufactured by Johnson&Johnson, approved in October 2022
• Elranatamab (ELREXFIO), manufactured by Pfizer, approved in August 2023  
• Talquetamab (TALVEY), manufactured by Johnson&Johnson, approved in August 2023  

Although commercially available, these therapies might also be received through a clinical trial, as they are being tested in a wider population and combined with other myeloma treatments (See Treatment Strategies with Bispecific Antibodies).